BMS gets FDA priority review for Breyanzi to treat LBCL after first-line therapy
The US agency has accepted the company’s supplemental Biologics License Application (sBLA) for the drug to expand its…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Feb 22
The US agency has accepted the company’s supplemental Biologics License Application (sBLA) for the drug to expand its…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Feb 22
The announcement builds on Moderna’s recent plans to expand in the Asia-Pacific region and will establish a local…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Feb 22
The company will establish new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong, to scale up its mRNA…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Jan 22
Samsung Biologics said that the transaction would advance Samsung Bioepis’ capabilities in biosimilar development and future performance in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Jan 22
APS03118 is a new drug that targets patients with various advanced cancer types, caused by rearranged during transfection…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Jan 22
The MHLW approval was based on positive data from the Phase 2 CodeBreaK 100, a first-in-human, open-label multicentre…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Jan 22
The transaction will add Fintepla (fenfluramine), approved by the US Food and Drug Administration (FDA) and the European…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Jan 22
The Series A financing round was jointly led by existing investor Netherton Investments, alongside new investor Dompé farmaceutici
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Jan 22
The oral medicine has been approved for the treatment of cystic fibrosis in young patients aged six to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Jan 22
The collaboration is expected to allow Stoke to receive potential milestone payments of up to $907m
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates